Brian J. Underdown

Brian Underdown joined Lumira Capital (formerly, MDS Capital Corp) in 1997. His focus has been on new company formation in both Canada and the United States. Prior to joining MDSCC, Dr. Underdown held a number of senior management positions in the biopharmaceutical industry and in universities. Dr. Underdown obtained his Ph.D. in immunology from McGill University and undertook post-doctoral studies at Washington University School of Medicine. During his academic career, he focused on immune-mediated diseases as well as vaccine development. During his tenure at MDSCC, Dr. Underdown has focused on new investment opportunities and building value as a board member in a number of companies including, ID Biomedical, Trillium Therapeutics and Cytochroma Inc. He has been actively involved in policy development and grant administration with a number of government and non-governmental organizations that support research, especially as it applies to commercial development.